How to Use a Mid-Year Rx Review to Build Stronger Client Relationships

For many employers, pharmacy conversations happen too late. 

Costs spike, renewal arrives, and decisions are made under pressure. By that point, options feel limited and trust is tested. 

A mid-year Rx review changes that dynamic. When used intentionally, it becomes one of the most effective ways brokers can strengthen client relationships and reinforce their role as strategic advisors. 

Why Timing Matters

Renewal season is reactive by nature. Mid-year reviews are proactive. 

By stepping in before renewal, brokers signal something important to their clients. Pharmacy oversight is not a once-a-year obligation. It is an ongoing responsibility. 

That shift in timing sets the foundation for stronger, more collaborative relationships. 

What a Mid-Year Rx Review Should Accomplish

A meaningful mid-year review is not about delivering another report. It is about creating clarity. 

At its best, a mid-year Rx review helps clients: 

• Understand what is driving pharmacy spend today. 
• Identify emerging risks before they escalate. 
• See how incentives influence outcomes. 
• Prepare for informed decisions later in the year. 

The goal is insight, not information overload. 

Where Brokers Add the Most Value

Brokers often underestimate the relational impact of mid-year reviews. 

When done well, these reviews demonstrate: 

• Proactive leadership. 
• Willingness to address complexity. 
• Commitment beyond renewal cycles.

Clients notice when their broker shows up early. 

Key Areas to Focus On

An effective mid-year Rx review does not require exhaustive analysis. It requires focus.

Spend Drivers and Trend Direction

Instead of rehashing historical totals, highlight:
• Which drugs or categories are driving change.
• Whether trends are accelerating or stabilizing.
• What is likely to carry into the next plan year.

This helps clients connect data to future impact.

Specialty Risk Exposure

Mid-year is the ideal time to discuss specialty medications.

Topics should include:
• High-cost claimant concentration
• New therapies entering the pipeline
• Potential financial exposure in the coming months

Addressing specialty risk early builds credibility.

Incentive Alignment

Review how current arrangements may influence outcomes.

Ask questions such as:
• Are formulary decisions aligned with lowest net cost?
• Where do vendor incentives exist?
• What assumptions are we making about pricing or rebates?

These discussions elevate the conversation beyond reporting.

Visibility Gaps

Identify where the client lacks insight.This might include:
• Limited data access
• Lack of clarity around sourcing decisions
• Unexplained variances in cost

Calling out blind spots positions the broker as an advocate.

How Mid-Year Reviews Strengthen Relationships

Mid-year Rx reviews do more than inform. They build trust.

Clients value brokers who:
• Anticipate challenges instead of reacting to them.
• Explain complexity in plain language.
• Create space for thoughtful discussion.
• Help them feel prepared, not surprised.

These moments accumulate. Over time, they redefine the relationship.

Setting Up Renewal for Success

Perhaps the most overlooked benefit of a mid-year review is what it does for renewal.

When issues are identified early:
• Renewal conversations are calmer.
• Decisions are more intentional.
• Expectations are clearer.
• Surprises are reduced.

Renewal becomes a continuation of strategy, not a scramble.

The Takeaway

A mid-year Rx review is not just a best practice. It is a signal.

It tells clients that their broker is engaged, informed, and invested in long-term outcomes, not just annual deliverables.

In a market where many relationships still revolve around renewal season, that signal makes a lasting impression.